These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18703395)

  • 1. [Calcineurin inhibitors minimisation and anti-proliferative strategies].
    Pascual J
    Nephrol Ther; 2008 Jun; 4 Suppl 1():S29-S35. PubMed ID: 18703395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
    Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK; Weir MR
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].
    Audard V
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S395-9. PubMed ID: 20129452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD
    Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proliferation signal inhibitors: what therapeutic protocols are followed in 2009?].
    Ladrière M
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S385-9. PubMed ID: 20129450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM; Grinyó JM
    Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
    Rintala JM; Savikko J; Rintala SE; von Willebrand E
    Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B
    Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation.
    Weintraub L; Li L; Kambham N; Alexander S; Concepcion W; Miller K; Wong C; Salvatierra O; Sarwal M
    Pediatr Transplant; 2008 Aug; 12(5):541-9. PubMed ID: 18564305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
    Sánchez Fructuoso A; Ruiz San Millán JC; Calvo N; Rodrigo E; Moreno MA; Cotorruelo J; Conesa J; Gómez-Alamillo C; Arias M; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reviewing the evidence for de novo immunosuppression with sirolimus.
    Flechner SM
    Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Review of clinical trials on minimization and interruption of calcineurin inhibitors (CNIs) and protocols without CNIs in the transplantation of different organs (kidney, heart, and liver)].
    Albano L
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S371-8. PubMed ID: 20129448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies to reduce nephrotoxicity.
    Kreis H
    Transplantation; 2001 Dec; 72(12 Suppl):S99-104. PubMed ID: 11833149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A; Campistol JM; Lario S; Oppenheimer F; Diekmann F
    Transplant Proc; 2007 Sep; 39(7):2138-41. PubMed ID: 17889117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic allograft nephropathy--a clinical syndrome: early detection and the potential role of proliferation signal inhibitors.
    Campistol JM; Boletis IN; Dantal J; de Fijter JW; Hertig A; Neumayer HH; Oyen O; Pascual J; Pohanka E; Ruiz JC; Scolari MP; Stefoni S; Serón D; Sparacino V; Arns W; Chapman JR
    Clin Transplant; 2009; 23(6):769-77. PubMed ID: 19719730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.